Company news

Ocular Therapeutix, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Ocular Therapeutix™ Receives FDA Agreement Under Special Protocol Assessment (SPA) for its First Pivotal Clinical Trial of OTX-TKI in Wet AMD

October 31, 2023

Ocular Therapeutix™ To Report Third Quarter 2023 Financial Results

October 23, 2023

Ocular Therapeutix™ Announces Initiation of its First Pivotal Clinical Trial of OTX-TKI in Wet AMD

October 2, 2023

Ocular Therapeutix™ to Present at the H.C. Wainwright 3rd Annual Ophthalmology Virtual Conference

August 8, 2023

Ocular Therapeutix™ Provides Second Quarter 2023 Financial Results and Corporate Update

August 6, 2023

Ocular Therapeutix™ To Report Second Quarter 2023 Financial Results

July 23, 2023

Ocular Therapeutix™ Announces Appointment of New Board Member

July 11, 2023

Ocular Therapeutix™ Announces 12-Month Topline Data from Ongoing U.S.-Based Phase 1 Clinical Trial Evaluating OTX-TKI for Treatment of Wet AMD

June 9, 2023

Ocular Therapeutix™ Completes Enrollment of the HELIOS Clinical Trial of OTX-TKI for the Treatment of Diabetic Retinopathy

June 6, 2023

Ocular Therapeutix™ To Present 12-Month Top-Line Data from U.S.-Based Phase 1 Clinical Trial of OTX-TKI in Wet Age-Related Macular Degeneration at the 2023 Clinical Trials at the Summit Annual Meeting

June 4, 2023

Ocular Therapeutix™ to Present at the Jefferies Global Healthcare Conference

May 31, 2023

Ocular Therapeutix™ to Present at the JMP Securities Life Sciences Conference

May 7, 2023

Ocular Therapeutix™ Provides First Quarter 2023 Financial Results and Corporate Update

May 7, 2023

Ocular Therapeutix™ To Present Data at the 2023 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting

April 27, 2023

Ocular Therapeutix™ To Report First Quarter 2023 Financial Results

April 23, 2023

Ocular Therapeutix™ To Present Pre-Clinical and Clinical Data at the 2023 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting

April 13, 2023

Ocular Therapeutix™ Provides Fourth Quarter and Year-End 2022 Results and Corporate Update

March 5, 2023

Ocular Therapeutix™ to Present at Cowen’s 43rd Annual Healthcare Conference

February 27, 2023

Ocular Therapeutix™ To Report Fourth Quarter and Year-End 2022 Financial Results

February 20, 2023

Ocular Therapeutix™ Announces Interim 10-month Data from the Ongoing U.S. Phase 1 Clinical Trial Evaluating OTX-TKI for the Treatment of Wet AMD

February 10, 2023

Ocular Therapeutix™ Provides 2022 Year End Corporate Update and Reviews Expected 2023 Milestones

January 5, 2023

Ocular Therapeutix™ to Participate at Three Upcoming Investor Conferences

November 7, 2022

Ocular Therapeutix™ Reports Third Quarter 2022 Financial Results and Business Update

November 6, 2022

Ocular Therapeutix™ To Report Third Quarter 2022 Financial Results

October 23, 2022

Ocular Therapeutix™ Announces Interim 7-month Data from U.S. Phase 1 Clinical Trial of OTX-TKI for the Treatment of Wet AMD

September 26, 2022

Ocular Therapeutix™ To Present Data at the American Academy of Ophthalmology (AAO) 2022 Annual Meeting

September 21, 2022

Ocular Therapeutix™ to Present at the H.C. Wainwright 24th Annual Global Investment Conference

September 6, 2022

Ocular Therapeutix™ to Present at the H.C. Wainwright 2nd Annual Ophthalmology Virtual Conference

August 9, 2022

Ocular Therapeutix™ Reports Second Quarter 2022 Financial Results and Business Update

August 7, 2022

Ocular Therapeutix™ To Report Second Quarter 2022 Financial Results

July 24, 2022

Ocular Therapeutix™ Announces Organizational Changes to Support Development for Retinal Diseases

June 7, 2022

Ocular Therapeutix™ to Present at the Jefferies Healthcare Conference

May 31, 2022

Ocular Therapeutix™ Reports First Quarter 2022 Financial Results and Business Update

May 8, 2022

Ocular Therapeutix™ To Present Pre-Clinical Data at the American Society of Gene & Cell Therapy (ASGCT) 25th Annual Meeting

May 2, 2022

Ocular Therapeutix™ to Report First Quarter 2022 Financial Results

April 25, 2022

Ocular Therapeutix™ to Present Pre-Clinical and Clinical Data at the 2022 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting

April 24, 2022

Ocular Therapeutix™ to Present Clinical Data at the 2022 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting

April 13, 2022

Ocular Therapeutix™ to Present at the Cowen 42nd Annual Healthcare Conference

March 3, 2022

Ocular Therapeutix™ Reports Fourth Quarter and Year-End 2021 Financial Results and Business Update

February 27, 2022

Ocular Therapeutix™ To Report Fourth Quarter and Year-End 2021 Financial Results

February 21, 2022

Ocular Therapeutix™ Announces Upcoming Presentation of Interim OTX-TKI Phase 1 Clinical Trial Data at Angiogenesis, Exudation, and Degeneration 2022 Meeting and OTX-TIC Phase 1 Clinical Trial at Glaucoma 360

February 10, 2022

AffaMed Therapeutics, licensee of DEXTENZA® in Certain Asian Markets, Doses Their First Patient in Clinical Trial Evaluating the Safety and Efficacy of DEXTENZA® in China in Cataract Surgery Patients

January 17, 2022

Ocular Therapeutix™ to Present at the H.C. Wainwright BioConnect 2022 Virtual Conference

January 3, 2022

Ocular Therapeutix™ Announces Topline Results for Phase 2 Clinical Trial of OTX-DED for the Short-Term Treatment of Dry Eye Disease

December 5, 2021

Ocular Therapeutix™ to Participate at Two Upcoming Investor Conferences

November 14, 2021

Ocular Therapeutix™ Announces Success in Patent Appeal Brought by Mati Therapeutics, Inc.

November 8, 2021

Ocular Therapeutix™ Reports Third Quarter 2021 Financial Results and Business Update

November 7, 2021

Ocular Therapeutix™ Announces Update from the Centers for Medicare and Medicaid Services (CMS) for the Reimbursement of DEXTENZA®

November 4, 2021

Ocular Therapeutix™ to Present Data at the American Academy of Optometry Annual Meeting 2021

October 31, 2021

Ocular Therapeutix™ To Report Third Quarter 2021 Financial Results

October 28, 2021

← Newer news releases · Older news releases →

Calls

The 5 newest of 18 calls. Every call is listed under its year.

Decks

The 5 newest of 14 decks. Every deck is listed under its year.